CN114213415A - 大环嘧啶衍生物 - Google Patents

大环嘧啶衍生物 Download PDF

Info

Publication number
CN114213415A
CN114213415A CN202111600011.XA CN202111600011A CN114213415A CN 114213415 A CN114213415 A CN 114213415A CN 202111600011 A CN202111600011 A CN 202111600011A CN 114213415 A CN114213415 A CN 114213415A
Authority
CN
China
Prior art keywords
alkyl
hydroxy
group
alkyloxy
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111600011.XA
Other languages
English (en)
Chinese (zh)
Inventor
G.S.M.蒂伊斯
B.肖恩杰斯
M.L.A.维塞勒
D.J-C.伯特洛特
M.维勒姆斯
M.维伊勒沃耶
W.C.J.埃姆布雷赫茨
B.维罗布洛维斯基
L.米波伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN114213415A publication Critical patent/CN114213415A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202111600011.XA 2014-04-03 2015-04-02 大环嘧啶衍生物 Pending CN114213415A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP14163443.6 2014-04-03
EP14163443 2014-04-03
EP14183747 2014-09-05
EP14183747.6 2014-09-05
PCT/EP2015/057399 WO2015150555A1 (en) 2014-04-03 2015-04-02 Macrocylic pyrimidine derivatives
CN201580018080.6A CN106164075B (zh) 2014-04-03 2015-04-02 大环嘧啶衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580018080.6A Division CN106164075B (zh) 2014-04-03 2015-04-02 大环嘧啶衍生物

Publications (1)

Publication Number Publication Date
CN114213415A true CN114213415A (zh) 2022-03-22

Family

ID=52781117

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202111600011.XA Pending CN114213415A (zh) 2014-04-03 2015-04-02 大环嘧啶衍生物
CN201580018080.6A Active CN106164075B (zh) 2014-04-03 2015-04-02 大环嘧啶衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580018080.6A Active CN106164075B (zh) 2014-04-03 2015-04-02 大环嘧啶衍生物

Country Status (21)

Country Link
US (1) US10017509B2 (https=)
EP (1) EP3126364B1 (https=)
JP (1) JP6529513B2 (https=)
KR (1) KR102390276B1 (https=)
CN (2) CN114213415A (https=)
AU (1) AU2015239098B2 (https=)
BR (1) BR112016021982B1 (https=)
CA (1) CA2942636C (https=)
CL (1) CL2016002461A1 (https=)
EA (1) EA031246B1 (https=)
ES (1) ES2667723T3 (https=)
IL (1) IL248005B (https=)
MA (1) MA39822A (https=)
MX (1) MX369798B (https=)
MY (1) MY185491A (https=)
NZ (1) NZ725399A (https=)
PE (1) PE20161362A1 (https=)
PH (1) PH12016501963A1 (https=)
SG (1) SG11201608240RA (https=)
UA (1) UA118219C2 (https=)
WO (1) WO2015150555A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI721104B (zh) 2016-02-19 2021-03-11 瑞典商斯普林特生物科技公司 6‐芳基或6‐雜芳基‐4‐嗎啉‐4‐芳基‐吡啶‐2‐酮化合物
ES2821400T3 (es) 2016-02-19 2021-04-26 Sprint Bioscience Ab Compuestos de 6-heterociclil-4-morfolin-4-ilpiridin-2-ona útiles para el tratamiento del cáncer y la diabetes
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
SI3672962T1 (sl) 2017-08-23 2022-06-30 Sprint Bioscience Ab Morfolinilpiridonske spojine
SI3672967T1 (sl) 2017-08-23 2022-04-29 Sprint Bioscience Ab Spojine azaindolilpiridona in diazaindolilpiridona
TW202325302A (zh) 2017-08-23 2023-07-01 瑞典商斯普林特生物科技公司 吡啶胺-吡啶酮及嘧啶胺-吡啶酮化合物
JP7199737B2 (ja) 2017-08-23 2023-01-06 スプリント バイオサイエンス アクティエボラーグ ピリジルピリドン化合物
US20230148005A1 (en) * 2020-02-18 2023-05-11 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
KR20230007369A (ko) * 2020-04-07 2023-01-12 아이테오스 벨지움 에스에이 암의 치료를 위한 ent 저해제로서의 거대환식 다이아민 유도체 및 이와 아데노신 수용체 길항제와의 조합물
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨（广东）医药科技有限公司 一种大环jak抑制剂及其应用
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用
WO2022020651A1 (en) * 2020-07-22 2022-01-27 Fog Pharmaceuticals, Inc. Amino acids
CN118139846A (zh) * 2021-09-23 2024-06-04 河南晟翔医药科技有限公司 一种egfr小分子抑制剂、含其的药物组合物及其用途
KR102613509B1 (ko) * 2021-12-15 2023-12-13 환인제약 주식회사 마크로사이클릭 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물
WO2024078263A1 (zh) * 2022-10-09 2024-04-18 药雅科技(上海)有限公司 大环杂环类化合物作为egfr抑制剂的制备及其应用
CN117229300A (zh) * 2023-03-12 2023-12-15 药雅科技(上海)有限公司 Egfr抑制剂的制备及其应用
WO2024094171A1 (zh) * 2022-11-04 2024-05-10 江苏恒瑞医药股份有限公司 取代的氨基嘧啶类化合物、其制备方法及其在医药上的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
AU2004224807A1 (en) 2003-03-24 2004-10-07 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
MXPA06007018A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolino con actividad anti-proliferativa.
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US8778919B2 (en) 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
WO2007058627A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives
WO2007059628A1 (en) 2005-11-24 2007-05-31 Oz Communications Inc. Method for securely associating data with http and https sessions
CA2687909C (en) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
US8318929B2 (en) 2008-03-10 2012-11-27 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines
JP2011522865A (ja) 2008-06-13 2011-08-04 ノバルティス アーゲー Ｉａ心不全および癌の治療に有用なプロテインキナーゼｄ阻害剤としての２，４’−ビピリジニル化合物
AU2010254056A1 (en) 2009-05-28 2011-12-15 Tetralogic Pharmaceuticals Corp. IAP inhibitors
CN102548987B (zh) 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 作为激酶抑制剂的氟取代化合物及其使用方法
TWI513695B (zh) 2009-10-27 2015-12-21 Merck Sharp & Dohme （１，１，１，３，３，３－六氟－２－羥基丙－２－基）苯基衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法

Also Published As

Publication number Publication date
US20170022202A1 (en) 2017-01-26
SG11201608240RA (en) 2016-10-28
PE20161362A1 (es) 2016-12-17
ES2667723T3 (es) 2018-05-14
UA118219C2 (uk) 2018-12-10
EP3126364A1 (en) 2017-02-08
EA201692003A1 (ru) 2017-06-30
AU2015239098B2 (en) 2019-08-01
AU2015239098A1 (en) 2016-09-29
EP3126364B1 (en) 2018-02-07
BR112016021982A2 (https=) 2017-08-15
CA2942636C (en) 2023-03-21
MA39822A (fr) 2018-02-06
IL248005B (en) 2018-12-31
KR20160142316A (ko) 2016-12-12
PH12016501963B1 (en) 2017-01-09
WO2015150555A1 (en) 2015-10-08
US10017509B2 (en) 2018-07-10
CL2016002461A1 (es) 2017-06-23
BR112016021982B1 (pt) 2022-07-26
PH12016501963A1 (en) 2017-01-09
CN106164075A (zh) 2016-11-23
MY185491A (en) 2021-05-19
CA2942636A1 (en) 2015-10-08
NZ725399A (en) 2023-01-27
JP2017509687A (ja) 2017-04-06
CN106164075B (zh) 2021-11-26
MX2016012992A (es) 2016-12-07
EA031246B1 (ru) 2018-12-28
MX369798B (es) 2019-11-21
KR102390276B1 (ko) 2022-04-22
JP6529513B2 (ja) 2019-06-12

Similar Documents

Publication Publication Date Title
CN106164075B (zh) 大环嘧啶衍生物
CN106132964B (zh) 大环吡啶衍生物
CN109311843B (zh) 作为PI3Kβ抑制剂的氮杂苯并咪唑衍生物
AU2015257456B2 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN106170288B (zh) 药物化合物
CN106132967B (zh) 作为ros1抑制剂的化合物
JP7213193B2 (ja) Ｎｉｋ阻害剤としての新規の置換アザインドリン誘導体
CN107108633B (zh) 作为PI3Kβ抑制剂的杂环基连接的咪唑并哒嗪衍生物
CN114981270A (zh) Mll1抑制剂和抗癌剂
CN119894908A (zh) Egfr抑制剂和其用途
EP3601254B1 (en) Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors
HK40003079A (en) Azabenzimidazole derivatives as pi3k beta inhibitors
HK40003076A (zh) 作为PI3Kβ抑制剂的二环吡啶、二环吡嗪、和二环嘧啶衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination